	Application No.	Applicant(s)	
	09/955,485	MOSKOWITZ ET AL.	
Notice of Allowability	Examiner	Art Unit	
-	Phyllis G. Spivack	1614	
The MAILING DATE of this communication app.  All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT of the Office or upon petition by the applicant. See 37 CFR 1.31	nears on the cover sheet with S (OR REMAINS) CLOSED in S) or other appropriate communication is S and MPEP 1308.	nication will be mailed in due cours	se. THIS
1. This communication is responsive to the Amendment filed February 18, 2004.			
2. The allowed claim(s) is/are 21, 22, 24-28, now renumbered 1-7.			
3. $\square$ The drawings filed on <u>19 September 2001</u> are accepted by			
<ul> <li>4.  Acknowledgment is made of a claim for foreign priority (a)  All b)  Some* c)  None of the:</li> <li>1.  Certified copies of the priority documents have 2.  Certified copies of the priority documents have 3.  Copies of the certified copies of the priority documents have 3.  Copies of the certified copies of the priority documents have 3.  Copies of the certified copies of the priority documents have 3.  Copies of the certified copies of the priority documents have 3.  Note that the priority documents have 3.  Note the priority documents have 3.  Note the priority documents have 3.  Note the priorit</li></ul>	ve been received. ve been received in Applicatio	n No	from the
International Bureau (PCT Rule 17.2(a)).			
* Certified copies not received:		to a supplying with the require	monts
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.			
6. ☐ CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.  (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached			
(a) ☐ including changes required by the Notice of Braitsperson of attended to the Notice of Attended to the Notice of Attended to the Notice of Braitsperson of the Notice of Attended to t			
(b) ☐ including changes required by the attached Examina	er's Amendment / Comment o		
Identifying indicia such as the application number (see 37 CFF each sheet, Replacement sheet(s) should be labeled as such i	Il the header according to ar a.		
7. DEPOSIT OF and/or INFORMATION about the de attached Examiner's comment regarding REQUIREMEN	posit of RIOLOGICAL MAT	ERIAL must be submitted. Note	the
Attachment(s)  1. ☐ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-94)  3. ☒ Information Disclosure Statements (PTO-1449 or PTO/S Paper No./Mail Date 3-15-04  4. ☐ Examiner's Comment Regarding Requirement for Depos of Biological Material	8) 6. ⊠ Interview S Paper No B/08), 7. ⊠ Examiner's		
		Phyllis G. Spivack Primary Examiner Art Unit: 1614	

Application/Control Number: 09/955,485

Art Unit: 1614

## **EXAMINER'S AMENDMENT**

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to Applicants, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

On page 18, line 16, of the specification, "No-" is <u>deleted</u> and --- NO- -- is <u>inserted</u> therefor.

Authorization for this examiner's amendment was given in a telephone interview with Danielle Herritt on June 7, 2004.

Application/Control Number: 09/955,485

Art Unit: 1614

The following is an Examiner's statement of Reasons for Allowance:

An Amendment filed February 18, 2004 is acknowledged. Claims 1-20, 23 and 29-35 are canceled. Claims 21, 22 and 24-28 remain under consideration.

An Information Disclosure Statement filed March 15, 2004 is further acknowledged and has been reviewed.

Claims 20, 21, 23, 24 and 28 were rejected under 35 U.S.C. 103 as being unpatentable over Myslivecek et al., <u>Neuroscience</u>, in the last Office Action. It was asserted Myslivecek teaches the substantially contemporaneous administration of the NO-increasing agent, L-arginine, with a physiologically active dopamine composition, in the brain.

Applicants have amended the claims such that only a simvastatin composition is recited as the physiologically active composition. Accordingly, the rejection of record under 35 U.S.C. 103 is withdrawn.

Two other rejections of record of claims 29-35 under 35 U.S.C. 103 are moot following the cancellation of the claims.

Claims 20-28 were rejected in the last Office Action under 35 U.S.C. 112, first paragraph, as not providing enablement for increased bioavailability of any physiologically active composition.

Following the amendments to independent claims 21 and 22, wherein the claims were limited to simvastatin compositions, the rejection of record under 35 U.S.C. 112, first paragraph, is withdrawn.

Art Unit: 1614

The prior art does not teach or suggest a method of increasing cerebral bioavailability specifically of a simvastatin composition comprising introducing the composition into the blood stream substantially contemporaneously with either L-arginine and/or another NO-increasing agents. NO-increasing agents are well known in the prior art. Pages 13-14 of the specification recite numerous examples. Thus claims 21, 22 and 24-28 are allowed in view of the contemporary knowledge of the art.

Any comments considered necessary by Applicants must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication should be directed to Phyllis G. Spivack at telephone number 571-272-0585.

Phyllis G. Spivack Primary Examiner Art Unit 1614

PHYLLIS SPINACK
PRIMARY EXAMINER

Phyllis SpiracK

Page 4

June 7, 2004